Thymosin Alpha 1 Vials
|Thymosin Alpha-1 95%|
|Molar Mass||3108.3 g/mol|
Thymosin Alpha 1, a research peptide, stands at the forefront of immunomodulatory exploration. Designed exclusively for laboratory research, this peptide is crafted to investigate its impact on various facets of the immune system.
Thymosin Alpha 1 is a synthetic version of a naturally occurring thymic peptide. Renowned for its immunomodulating properties, this peptide serves as a valuable tool for researchers delving into the complexities of immune response and related pathways.
The primary application of Thymosin Alpha 1 in research lies in its potential to modulate the immune system. Researchers can utilize this peptide to explore its effects on immune cells, cytokine production, and overall immune function.
Thymosin Alpha 1 and Cystic Fibrosis
Studies suggest that Thymosin Alpha 1 may hold promise in the context of Cystic Fibrosis (CF). Research in this area explores the peptide’s potential in addressing immune dysregulation associated with CF.
Thymosin Alpha 1 and Sepsis
Thymosin Alpha 1 has been investigated for its role in managing sepsis, a life-threatening condition resulting from a dysregulated immune response. Research indicates potential benefits in modulating immune function in septic patients.
Thymosin Alpha 1 and Lung Cancer
Exploratory research suggests a connection between Thymosin Alpha 1 and lung cancer. Investigations in this area aim to understand the peptide’s potential role in immune-mediated responses against lung cancer cells.
In summary, Thymosin Alpha 1 Peptide emerges as a focal point for immunological research. With potential benefits spanning applications in Cystic Fibrosis, sepsis management, and lung cancer studies, Thymosin Alpha 1 provides researchers with a platform to deepen our understanding of immunomodulation.
- Romani, L., Oikonomou, V., Moretti, S., Iannitti, R. G., D’Adamo, M. C., Villella, V. R., Pariano, M., Sforna, L., Borghi, M., Bellet, M. M., Fallarino, F., Pallotta, M. T., Servillo, G., Ferrari, E., Puccetti, P., Kroemer, G., Pessia, M., Maiuri, L., Goldstein, A. L., & Garaci, E. (2017). Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nature Medicine, 23(5), 590-600. https://doi.org/10.1038/nm.4305. [Read More].
- Garaci E, Lopez M, Bonsignore G, Della Giulia M, D’Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995 Dec;31A(13-14):2403-5. doi: 10.1016/0959-8049(95)00477-7. PMID: 8652276. [Read More].
- Wang FY, Fang B, Qiang XH, Yu TO, Zhong JR, Cao J, Zhou LX. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis. Biomed Res Int. 2016;2016:9508493. doi: 10.1155/2016/9508493. Epub 2016 May 31. PMID: 27340674; PMCID: PMC4906180. [Read More].